Company announcement - Announcements and Circulars - Investor - XZenith Biopharm

Investor relations

Company announcement Performance presentation

Performance promotion

Company announcement

All

VOLUNTARY ANNOUNCEMENT SUCCESSFUL RENEWAL AND INCLUSION OF THE INNOVATIVE DRUG ANJIUWEI IN THE 2025 NRDL
VOLUNTARY ANNOUNCEMENT XUANYUENING, AN INNOVATIVE DRUG, FIRST INCLUDED IN THE NRDL
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2025
Notification Letter and Reply Form to Non-registered Shareholders
Notification Letter and Reply Form to Registered Shareholders
INSIDE INFORMATION FILING WITH THE CSRC FOR PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY
INSIDE INFORMATION PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2025
VOLUNTARY ANNOUNCEMENT NG-350A GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA
VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT OF PHASE III CLINICAL STUDY DATA OF BIREOCICLIB FOR FIRST-LINE TREATMENT OF HR+/HER2 - ADVANCED BREAST CANCER AT ESMO 2025

<1 2 3 >